Enzon Reveals New LNA Targets

Enzon Pharmaceuticals today announced new novel Locked Nucleic Acid (LNA) programs directed against, the Androgen receptor (AR) and Phosphoinositide 3-kinase (PI3K/Akt)

BRIDGEWATER, NJ, USA | mARCH 19, 2009 | Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced new novel Locked Nucleic Acid (LNA) programs directed against, the Androgen receptor (AR) and Phosphoinositide 3-kinase (PI3K/Akt). These targets are linked to a broad spectrum of cancers. Enzon has licensed eight novel LNA targets from Santaris Pharma A/S.

The abstracts related to these new targets and other Enzon programs are now available at www.aacr.org. These data will be presented at the upcoming 2009 Annual Meeting of the American Association for Cancer Research (AACR) being held April 18-22, 2009 in Colorado.

“Novel releasable PEG-nanoparticles enhance delivery of RNA antagonist oligonucleotides in tumor cells and in mice” (Abstract #646)
Poster Presentation from 8:00 am to 12:00 pm local time on Sunday, April 19, 2009.

“EZN-2208, a novel pegylated SN-38 drug conjugate, markedly inhibits tumor growth and metastatic spreading of human neuroblastoma” (Abstract #1699)
Poster Presentation from 1:00 to 5:00 pm local time on Sunday, April 19, 2009.

“Androgen receptor (AR) down regulation by locked nucleic acid antisense oligonucleotides specifically inhibits the growth of AR-positive tumor cells” (Abstract #4631)
Poster Presentation from 1:00 to 5:00 pm local time on Tuesday, April 21, 2009.

“The antitumor activity of EZN-4150, a potent LNA-based PIK3CA antagonist” (Abstract #4634)
Poster Presentation from 1:00 to 5:00 pm local time on Tuesday, April 21, 2009.

“EZN-3042, a novel locked nucleic acid oligonucleotide against survivin, inhibits survivin expression and confers taxol sensitivity” (Abstract #4633)
Poster Presentation from 1:00 to 5:00 pm local time on Tuesday, April 21, 2009.

“EZN-3920, an LNA antisense oligonucleotide RNA antagonist, down modulates HER3 expression and PI3K/Akt signaling pathway and enhances antiproliferative effect of Gefitinib in tumor cells” (Abstract #4630)
Poster Presentation from 1:00 to 5:00 pm local time on Tuesday, April 21, 2009.

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing, manufacturing and commercializing important medicines for patients with cancer and other life-threatening conditions. The Company has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. Enzon’s drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform and the Locked Nucleic Acid (LNA) technology. Enzon’s PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden our revenue base.

Further information about Enzon and this press release can be found on the Company’s web site at www.enzon.com.

SOURCE: Enzon Pharmaceuticals, Inc.

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top